Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future
about
Hypersensitivity Responses in the Central Nervous SystemCSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.Early response index: a statistic to discover potential early stage disease biomarkers.Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study.Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cellsOxidative stress-related biomarkers in multiple sclerosis: a review.Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.Serum Neuroinflammatory Disease-Induced Central Nervous System Proteins Predict Clinical Onset of Experimental Autoimmune Encephalomyelitis.Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up.Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis.Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases.The tension between early diagnosis and misdiagnosis of multiple sclerosis.Acute disseminated encephalomyelitis in an elderly patient.Expert Review of Clinical Immunology 10-year anniversary issue. Foreword.Detection of Glycan Shedding in the Blood: New Class of Multiple Sclerosis Biomarkers?Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis.
P2860
Q26779177-D6ACB748-97E0-41DF-83F2-BBCF72DBC939Q31144959-4C269E17-B971-4E7A-AC02-026FC95859CEQ33827677-CECD4AE5-3008-4E15-84FE-D7E5924E8CECQ35907244-B0E5A63C-1948-4D4D-BCD1-47FBF9E45B5FQ37212300-7B4190A6-C637-480B-AD91-1A742D7854ECQ38841957-35152DE4-8E52-4660-A481-067E0AC96823Q38984981-E858342C-6C58-4640-AA9B-AE5C2583DF10Q41026569-6BBC0634-9B07-4EB2-998C-A5667F6CF032Q41236543-CA84AB2B-8FA0-4D0E-ACAD-691517F90F47Q41675007-C80034B0-E942-4E05-810B-549245D14DA3Q42696477-B78A1E1E-1C05-4860-BF33-9C0FCA03B812Q47800390-0A139AE6-4132-445B-9024-BD90CE2BB4E3Q47850068-A8E88271-56F1-41A3-A217-DBA69698AAE3Q48055292-DB7509E0-9D42-4632-8CFA-03542EDC9C7EQ55262746-7E9296AF-1BCA-4071-9AA0-9833C4968113Q55282776-BD9C7225-26E4-4E6A-88F0-51FB00AE0C98
P2860
Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Body fluid biomarkers in multi ...... e clinic now and in the future
@ast
Body fluid biomarkers in multi ...... e clinic now and in the future
@en
type
label
Body fluid biomarkers in multi ...... e clinic now and in the future
@ast
Body fluid biomarkers in multi ...... e clinic now and in the future
@en
prefLabel
Body fluid biomarkers in multi ...... e clinic now and in the future
@ast
Body fluid biomarkers in multi ...... e clinic now and in the future
@en
P2093
P2860
P1476
Body fluid biomarkers in multi ...... e clinic now and in the future
@en
P2093
Johanna Webb
Olaf Stuve
William Haskins
P2860
P356
10.1586/1744666X.2015.991315
P577
2014-12-18T00:00:00Z